Abstract:Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations.

Paradoxical eruption exclusively located at ear in psoriatic patients treated with biologics: a case series

A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis

Paradoxical Psoriasis: A Dermoscopic and Histopathologic Teaching Points

Skin Related Paradoxical Adverse Events (Mainly Psoriasis) During Il-17 Blockage: A Systematic Review

Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review

Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review

Intraindividual Genome Expression Analysis Reveals a Specific Molecular Signature of Psoriasis and Eczema.

Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis

Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options

Psoriasis paradox-infliximab-induced psoriasis in a patient with Crohn's disease: a case report and mini-review

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

Eczematous reactions in patients with plaque psoriasis receiving biological therapy: an observational study

Biologic anti-IL17 drugs in erythrodermic psoriasis

Paradoxical psoriasis induced by IL-17 antagonists

Paradoxical Eczema Associated With Interleukin-17A Inhibitor Use in a Patient With Generalized Pustular Psoriasis Accompanied by Asthma

An 8-Year Retrospective Real-Life Study

Concomitant sarcoidosis, psoriasis, and eczema – immune patterns on the skin

Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Paradoxical reaction to IL-17A inhibitor: a case report and literature review

Allergic Contact Dermatitis in Psoriasis Patients: Typical, Delayed, and Non-Interacting.